Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN versus MOXAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN versus MOXAM.
FLOXIN vs MOXAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally every 12 hours for 10-14 days; ophthalmic solution: 1-2 drops in affected eye(s) every 2-4 hours for 2 days, then 1-2 drops 4 times daily for 10 days; otic solution: 5-10 drops in affected ear(s) twice daily for 10-14 days.
400 mg orally every 24 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life of 10-14 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe cases).
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
Approximately 70-90% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10-30% eliminated in feces via biliary excretion.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic